Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform.
Arecor is leveraging this platform to (i) develop a portfolio of proprietary products for diabetes care and (ii) to deliver superior reformulations of its partners proprietary products.
Arecor is committed to leveraging its ArestatTM platform to develop a portfolio of proprietary products enabling improved treatment for diabetes care via the innovative reformulations of approved proteins and peptides.
Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would simply not be possible using conventional formulation science.
The Downing FOUR VCT PLC Healthcare Technology Fund is managed by Downing LLP